Lexaria Bioscience (LEXX) Short term Debt (2011 - 2022)

Lexaria Bioscience has disclosed Short term Debt across 12 years of filings, most recently posting $7906.0 for Q2 2022.

• Short term Debt for Q2 2022 came in at $7906.0, up 497.13% year-over-year; the trailing twelve-month figure through May 2022 was $7906.0 (up 497.13% YoY), and the FY2021 annual result was $7926.0, changed N/A from the prior year.
• Short term Debt came in at $7906.0 for Q2 2022 at Lexaria Bioscience, up from $7817.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $206806.0 in Q1 2021 to a low of $1324.0 in Q2 2021.
• The 5-year median for Short term Debt is $8518.0 (2018), against an average of $31642.8.
• Across the five-year window, Short term Debt slumped 98.02% in 2018 and jumped 12825.38% in 2021, its largest moves.
• Lexaria Bioscience's Short term Debt stood at $21654.0 in 2018, then jumped by 71.79% to $37200.0 in 2019, then soared by 134.37% to $87185.0 in 2020, then sank by 91.03% to $7817.0 in 2021, then increased by 1.14% to $7906.0 in 2022.
• The last three Short term Debt figures came in at $7906.0 (Q2 2022), $7817.0 (Q4 2021), and $7926.0 (Q3 2021), per Business Quant data.